DNMT3A mutations have been associated with poor outcomes in some (RCMD and RAEB) but not all types of MDS (Cazzola, Della Porta, and Malcovati 2013; Walter et al. 2011). In addition, Bejar et al. (2014) observed that DNMT3A mutations predict shorter overall survival following hematopoietic stem cell transplantation. In RARS, DNMT3A mutations often co-occur with SF3B1 mutations, and no association between DNMT3A mutations and poor outcome is observed (Bejar et al. 2012; Cazzola, Della Porta, and Malcovati 2013).
Suggested Citation: Strickland, S., A. Kim. 2014. DNMT3A Mutations in Myelodysplastic Syndromes. My Cancer Genome https://www.mycancergenome.org/content/disease/myelodysplastic-syndromes/dnmt3a/322/ (Updated September 23).